Free Trial

SI-BONE (SIBN) Stock Price, News & Analysis

-0.62 (-4.42%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
375,790 shs
Average Volume
395,943 shs
Market Capitalization
$552.63 million
P/E Ratio
Dividend Yield
Price Target

SI-BONE MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
103.5% Upside
$27.29 Price Target
Short Interest
6.84% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.14mentions of SI-BONE in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$310,659 Sold Last Quarter
Proj. Earnings Growth
From ($0.95) to ($0.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

Medical Sector

138th out of 915 stocks

Surgical & Medical Instruments Industry

20th out of 96 stocks

SIBN stock logo


SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

SIBN Stock Price History

SIBN Stock News Headlines

JMP Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)
Piper Sandler Keeps Their Buy Rating on SI-Bone (SIBN)
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights
SIBN Apr 2024 2.500 put
SIBN Jul 2024 10.000 put
When Will SI-BONE, Inc. (NASDAQ:SIBN) Become Profitable?
See More Headlines
Receive SIBN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$138.89 million
Book Value
$4.02 per share


Free Float
Market Cap
$552.63 million

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

SIBN Stock Analysis - Frequently Asked Questions

Should I buy or sell SI-BONE stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SIBN shares.
View SIBN analyst ratings
or view top-rated stocks.

What is SI-BONE's stock price target for 2024?

6 equities research analysts have issued 1 year price objectives for SI-BONE's stock. Their SIBN share price targets range from $24.00 to $33.00. On average, they expect the company's stock price to reach $27.29 in the next twelve months. This suggests a possible upside of 103.5% from the stock's current price.
View analysts price targets for SIBN
or view top-rated stocks among Wall Street analysts.

How have SIBN shares performed in 2024?

SI-BONE's stock was trading at $20.99 at the beginning of 2024. Since then, SIBN shares have decreased by 36.1% and is now trading at $13.41.
View the best growth stocks for 2024 here

When is SI-BONE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our SIBN earnings forecast

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) announced its earnings results on Monday, February, 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm earned $38.86 million during the quarter, compared to the consensus estimate of $38.60 million. SI-BONE had a negative trailing twelve-month return on equity of 25.14% and a negative net margin of 29.93%.

What ETF holds SI-BONE's stock?

iShares U.S. Medical Devices ETF holds 246,858 shares of SIBN stock, representing 0.07% of its portfolio.

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $162.0 million-$165.0 million, compared to the consensus revenue estimate of $163.6 million.

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE Chief Executive Officer Jeffrey Dunn on Jeffrey Dunn has an approval rating of 41% among the company's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), RTX (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

SI-BONE (SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (6.00%), Vanguard Group Inc. (5.98%), Champlain Investment Partners LLC (5.95%), Bellevue Group AG (2.77%), Silvercrest Asset Management Group LLC (2.57%) and Kent Lake Capital LLC (1.02%). Insiders that own company stock include Anshul Maheshwari, Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Michael A Pisetsky, Mika Nishimura and Timothy E Davis Jr.
View institutional ownership trends

How do I buy shares of SI-BONE?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does SI-BONE have any subsidiaries?
The following companies are subsidiares of SI-BONE: SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.
Read More
This page (NASDAQ:SIBN) was last updated on 5/24/2024 by Staff

From Our Partners